Guidance
Reporting adverse incidents: coronary stents
For manufacturers reporting adverse incidents with coronary stents under the European vigilance system.
Documents
Details
MHRA’s guidance on when to report adverse incidents with coronary stents has been superseded by the European Commission’s guidance.
You need to read this alongside the European Commission’s guidelines on the vigilance system for medical devices.
Updates to this page
Published 1 January 2014
Last updated 4 October 2016
show all updates
-
MHRA’s guidance on when to report adverse incidents with coronary stents has been superseded by the European Commission’s guidance. We have updated our links accordingly.
-
First published.